Vinicius Ernani, M.D.

  1. Oncologist
  1. Peng Y, Li D, Wampfler JA, Luo YH, Kumar AV, Gu Z, Kosuru N, Yu NY, Wang Z, Leventakos K, Ernani V, Yang P. Targeted therapy‑associated cardiotoxicity in patients with stage‑IV lung cancer with or without cardiac comorbidities. Oncol Rep. 2025 Feb; 53 (2) Epub 2024 Dec 20
    View PubMed
  2. Bodor JN, Xiu J, Ernani V, Kaur S, Mamdani H, Ou SHI, Ma PC, Borghaei H, Clapper ML, VanderWalde A, Treat J. Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort. Clin Lung Cancer. 2024 Nov; 25 (7):e312-e315.e1 Epub 2024 May 03
    View PubMed
  3. Karigyo CJT, Pessoa BMS, Nicacio SP, Terwilliger E, Costa P, Santos PRD, Ernani V, Seetharam M, Murakami AN, Batalini F. Cardiac Tumors: Review. Braz J Cardiovasc Surg. 2024 Jul 22; 39 (6):e20230405 Epub 2024 July 22
    View PubMed
  4. Peng Y, Kumar AV, Gu Z, Kosuru N, Wampfler JA, Reck Dos Santos PA, Yu NY, D'Cunha J, Ernani V, Costello CM, Yang P. Dermatologic toxicity associated with targeted and immunotherapies in stage-IV non-small cell lung cancer patients: A 14-year cohort. J Am Acad Dermatol 2024 Jul; 91 (1):172-175 Epub 2024 Mar 29
    View PubMed
  5. Peng Y, Ernani V, Liu D, Guo Q, Hopps M, Cappelleri JC, Gupta R, de Andrade M, Chen J, Yi ES, Yang P. Lung adenocarcinoma patients with ROS1-rearranged tumors by sex and smoking intensity. Heliyon. 2024 Apr 15; 10(7):e28285. Epub 2024 Mar 16.
    View PubMed
  6. Rivera-Concepcion J, Lo YC, Uprety D, Adjei AA, Ernani V, Leventakos K. A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms. Current Problems in Cancer: Case Reports. 2024; 13:100284
  7. Desai A, Smith CJ, Ashara Y, Orme JJ, Zanwar S, Potter A, Hocum C, Moffett JN, Schwecke AJ, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Molina J, Dimou A, Mansfield AS, Parikh K, Leventakos K. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer. Clin Lung Cancer. 2023 Dec; 24 (8):689-695.e1 Epub 2023 Sept 17
    View PubMed
  8. Agarwal M, Liu A, Almquist D, Langlais BT, Leventakos K, Yu NY, Manochakian R, Ernani V. Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status. Cancer. 2023 Nov 15; 129 (22):3546-3553 Epub 2023 Aug 07
    View PubMed
  9. Agarwal M, Liu A, Langlais BT, Leventakos K, Yu NY, Almquist D, Manochakian R, Ernani V. Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3. Clin Lung Cancer. 2023 Nov; 24 (7):591-597 Epub 2023 May 26
    View PubMed
  10. Campany ME, Reck Dos Santos PA, Donato BB, Alwardt CM, Ernani V, D'Cunha J, Beamer SE. Hyperthermic intrapleural chemotherapy: an update. J Thorac Dis. 2023 Sep 28; 15 (9):5064-5073 Epub 2023 Aug 11
    View PubMed
  11. Ernani V, Appiah AK, Rodriguez D, Kusne Y, Beamer SE, Ravanbakhsh S, Jaroszewski D, Reck Dos Santos P, Sio TT, Yu N, Yang P, Schild S, D'Cunha J. Lobar versus sublobar resection for atypical lung carcinoid: An analysis from the National Cancer Database. Cancer. 2023 Mar 15; 129 (6):860-866 Epub 2022 Dec 22
    View PubMed
  12. Du L, Ernani V, Liu A, Schild SE, Jaroszewski DE, Cassivi SD, Beamer SE, Luo YH, Wampfler JA, Santos PARD, Wigle D, Sun D, Shen KR, Yang P. Prognostic factors in resected pulmonary carcinoid tumors: A retrospective study with 10 years of follow‑up. Oncol Lett. 2023 Feb; 25 (2):80 Epub 2023 Jan 10
    View PubMed
  13. Desai A, Rakshit S, Bansal R, Ashara Y, Potter A, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Schwecke A, Moffett N, Hocum C, Leventakos K, Adjei A, Marks R, Molina J, Mansfield AS, Chen ZM, Dimou A. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report. Cancer Treat Res Commun. 2023; 36:100743. Epub 2023 Jul 13.
    View PubMed
  14. Dos Santos PAR, Li Y, Ernani V, D'Cunha J, Aubry MC, Yang P. Clinical outcomes of stage-IV non-small-cell lung cancer in young patients and the impact of tumor markers. Cancer Treat Res Commun. 2023; 36:100723 Epub 2023 June 12
    View PubMed
  15. Yu NY, DeWees TA, Voss MM, Breen WG, Chiang JS, Ding JX, Daniels TB, Owen D, Olivier KR, Garces YI, Park SS, Sarkaria JN, Yang P, Savvides PS, Ernani V, Liu W, Schild SE, Merrell KW, Sio TT. Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 Dec; 23 (8):e526-e535 Epub 2022 Aug 10
    View PubMed
  16. Gao RW, Day CN, Yu NY, Bush A, Amundson AC, Prodduturvar P, Majeed U, Butts E, Oliver T, Schwecke AJ, Moffett JN, Routman DM, Breen WG, Potter AL, Rivera-Concepcion J, Hoppe BS, Schild SE, Sio TT, Lou Y, Ernani V, Ko S, Olivier KR, Merrell KW, Garces YI, Manochakian R, Harmsen WS, Leventakos K, Owen D. Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab. Lung Cancer. 2022 Aug; 170:58-64 Epub 2022 June 13
    View PubMed
  17. Ernani V, Du L, Ross HJ, Yi JE, Wampfler JA, Schild SE, Xie H, Swanson KL, Tazelaar HD, Yang P. Gastroesophageal reflux disease and paraneoplastic neurological syndrome associated with long-term survival in limited stage small-cell lung cancer. Thorac Cancer. 2022 Apr; 13 (7):925-933 Epub 2022 Feb 23
    View PubMed
  18. Yu NY, Sio TT, Ernani V, Savvides P, Schild SE. Role of Prophylactic Cranial Irradiation in Extensive-Stage Small Cell Lung Cancer. J Natl Compr Canc Netw. 2021 Dec; 19 (12):1465-1469
    View PubMed
  19. Almquist DR, Ernani V, Sonbol MB. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: DIPNECH. Curr Opin Pulm Med. 2021 Jul 1; 27 (4):255-261
    View PubMed
  20. Owonikoko TK, Dwivedi B, Chen Z, Zhang C, Barwick B, Ernani V, Zhang G, Gilbert-Ross M, Carlisle J, Khuri FR, Curran WJ, Ivanov AA, Fu H, Lonial S, Ramalingam SS, Sun SY, Waller EK, Sica GL. YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype. J Thorac Oncol. 2021 Mar; 16 (3):464-476 Epub 2020 Nov 25
    View PubMed
  21. Keit E, Coutu B, Zhen W, Zhang C, Lin C, Bennion N, Ganti AK, Ernani V, Baine M. Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer. Ann Transl Med. 2021 Feb; 9 (3):227
    View PubMed
  22. Almquist D, Ernani V. The Road Less Traveled: A Guide to Metastatic ROS1-Rearranged Non-Small-Cell Lung Cancer. JCO Oncol Pract. 2021 Jan; 17 (1):7-14 Epub 2020 Nov 19
    View PubMed
  23. Grinnell M, Appiah AK, Baine M, Ernani V, Marr A, Zhang C, Zhen W, Buddharaju LNR, Smith LM, Ganti AK. Adjuvant chemotherapy following SBRT for early stage non-small cell lung cancer (NSCLC) in older patients. J Geriatr Oncol. 2020 Sep; 11 (7):1145-1153 Epub 2020 May 07
    View PubMed
  24. Ernani V, Jahan R, Smith LM, Marr AS, Kimbrough SE, Kos ME, Tijerina J, Pivovar S, Lakshmanan I, Ketcham M, Rauth S, Mallya K, Nasser MW, Jain M, Kessinger A, Batra SK, Ganti AK. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study. Cancer Treat Res Commun. 2020; 22:100162 Epub 2019 Oct 07
    View PubMed
  25. Ernani V, Appiah AK, Baine MJ, Smith LM, Ganti AK. The impact of histology in the outcomes of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) and adjuvant chemotherapy. Cancer Treat Res Commun. 2020; 24:100197 Epub 2020 July 21
    View PubMed
  26. Ernani V, Stinchcombe TE. Management of Brain Metastases in Non-Small-Cell Lung Cancer. J Oncol Pract. 2019 Nov; 15 (11):563-570
    View PubMed
  27. Ernani V, Appiah AK, Marr A, Zhang C, Zhen W, Smith LM, Ganti AK. Adjuvant Systemic Therapy in Patients With Early-Stage NSCLC Treated With Stereotactic Body Radiation Therapy. J Thorac Oncol. 2019 Mar; 14 (3):475-481 Epub 2018 Nov 29
    View PubMed
  28. Ernani V, Ganti AK. Immunotherapy in treatment naive advanced non-small cell lung cancer. J Thorac Dis. 2018 Feb; 10 (Suppl 3):S412-S421
    View PubMed
  29. Palacio S, Hosein PJ, Reis I, Akunyili II, Ernani V, Pollack T, Macintyre J, Restrepo MH, Merchan JR, Rocha Lima CM. The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. J Gastrointest Oncol. 2018 Feb; 9 (1):135-139
    View PubMed
  30. Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, Pakkala S, Pillai RN, Owonikoko TK, Curran WJ, Belani CP, Khuri FR, Ramalingam SS. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review. JAMA Oncol. 2017 Aug 1; 3 (8):1120-1129
    View PubMed
  31. Ernani V, Steuer CE, Jahanzeb M. The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer. Annu Rev Med. 2017 Jan 14; 68:153-168 Epub 2016 Sept 07
    View PubMed
  32. Ernani V, Kumar M, Chen AY, Owonikoko TK. Systemic treatment and management approaches for medullary thyroid cancer. Cancer Treat Rev. 2016 Nov; 50:89-98 Epub 2016 Sept 10
    View PubMed
  33. Kumar M, Ernani V, Owonikoko TK. Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. Mol Aspects Med. 2015 Nov; 45:55-66 Epub 2015 July 14
    View PubMed
  34. Ernani V, Saba NF. Oral Cavity Cancer: Risk Factors, Pathology, and Management. Oncology. 2015; 89 (4):187-95 Epub 2015 June 17
    View PubMed
  35. Chapman-Fredricks J, Blieden C, Sandoval JD, Ernani V, Ikpatt OF. Acute spontaneous tumor lysis syndrome as the initial presentation of ALK-positive diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol. 2014 Apr; 22 (4):317-21
    View PubMed
  36. Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, Levi JU, Rocha-Lima CM. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012 May 29; 12:199
    View PubMed
  37. Bustinza-Linares E, Socola F, Ernani V, Miller SA, Trent JC. Extraskeletal myxoid chondrosarcoma with small bowel metastasis causing bowel obstruction. Case Rep Oncol Med. 2012; 2012:621025 Epub 2012 Nov 18
    View PubMed
  38. Paes FM, Ernani V, Hosein P, Serafini AN. Radiopharmaceuticals: when and how to use them to treat metastatic bone pain. J Support Oncol. 2011 Nov-Dec; 9 (6):197-205
    View PubMed
  39. Toneto MG, Hoffman A, Conte AF, Schambeck JL, Ernani V, Souza HP. Extended lymphadenectomy (D2) in the treatment for gastric cancer - analysis of postoperative complications. Revista do Colegio Brasileiro de Cirurgioes (Journal of the Brazilian College of Surgeons). 2008; 35(4):228-234.